Eilean Therapeutics  today announced the presentation of preclinical data for its novel, brain-permeable CDK2 inhibitor at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.

Eilean Therapeutics LLC today announced the presentation of data for its brain- and lung-permeable pan-EGFR inhibitor, ZE77-0273 is a reversible small-molecule drug candidate that demonstrates broad activity against resistance mutations in EGFR-mutant non-small cell lung cancer (NSCLC), a high selectivity index versus wild-type EGFR, and a wide therapeutic window characterized by excellent safety and tolerability.

Eilean Therapeutics LLC, a biopharmaceutical company targeting escape mutations in hematologic and solid malignancies, today announced that an abstract related to the company’s first-in-class oral MALT1 degrader has been accepted for a poster presentation at the upcoming American Society of Hematology (ASH) Annual Meeting.

Eilean Therapeutics AU Pty Ltd, a biopharmaceutical company dedicated to discovering and developing best-in-class and first-in-class small molecule inhibitors to target escape mutations in hematologic and solid malignancies, has joined The Leukemia & Lymphoma Society (LLS) in the groundbreaking collaborative Beat AML® Master Clinical Trial.

Eilean Therapeutics LLC, is pleased to announce that the U.S. Food and Drug Administration (FDA) has cleared the IND for lomonitinib (ZE46-0134), allowing the company to proceed with a Phase 1 clinical trial in FLT3 mutated relapsed/refractory (R/R) AML.

Eilean Therapeutics LLC announces the clearance from the Human Research Ethics Committee in Australia for lomonitinib (ZE46-0134) allowing the company to proceed with a Phase I clinical trial in relapsed/refractory (R/R) AML.

Eilean Therapeutics Australia Pty, Ltd, received clearance from the Human Research Ethics Committee in Australia to begin a Phase 1 trial of balamenib (ZE63-0302).

Eilean Therapeutics LLC announced the acquisition of Ness Therapeutics Inc (Ness) in an all-equity transaction.

Eilean Therapeutics LLC today announced the clearance from the Human Research Ethics Committee in Australia to begin human dosing in the Phase 1 clinical program of eiletoclax, a highly potent and selective BCL2 inhibitor.

Eilean Therapeutics LLC, today announced the completion of a single ascending dose Phase 1 clinical study of lomonitinib and initiation of a multiple ascending dose Phase 1 program.

Eilean Therapeutics LLC announced the initiation of human dosing in the Phase 1 clinical program of ZE46-0134, a highly potent and selective pan-FLT3 inhibitor that targets clinically relevant FLT3 mutations including the FLT3 gatekeeper mutation, while sparing the wild type form of the protein.